Advanced search
1 file | 569.85 KB Add to list

Towards the development of a RNAi-based topical treatment for psoriasis : proof-of-concept in a 3D psoriasis skin model

Eline Desmet, Mireille Van Gele (UGent) , Lynda Grine (UGent) , Katrien Remaut (UGent) and Jo Lambert (UGent)
(2018) EXPERIMENTAL DERMATOLOGY. 27(5). p.463-469
Author
Organization
Abstract
RNA interference has emerged as a powerful tool for therapeutic gene silencing, as it offers the possibility to silence virtually any known pathology-causing gene. However, in vivo delivery of RNAi molecules is hampered by their unfavourable physicochemical characteristics and susceptibility to degradation by endogenous enzymes. To overcome these limitations, we recently developed an elastic liposomal formulation, called DDC642, as topical delivery system of therapeutic RNAi molecules for skin disorders. In this study, we validated the therapeutic efficacy of DDC642-encapsulated RNAi molecules in the treatment of psoriasis using 3 different in vitro models: a standardized keratinocyte monolayer culture, psoriasis-induced keratinocytes and a psoriasis-reconstructed skin model. Four genes (IL22RA1, KRT17, DEFB4 and TSLP), known to be upregulated in psoriatic lesions, and thereby key players in psoriasis pathogenesis were selected. Moreover, the possibility of using a combined siRNA therapy in the topical treatment of psoriasis was explored. Results indicate a successful gene silencing of each different target, both at mRNA and protein levels. Additionally, siRNA-DDC642 treatment resulted in a reduced expression of specific psoriasis markers, indicating their potential in future therapeutic approach. The examined siRNA combination (ie simultaneous knockdown of KRT17, DEFB4 and TSLP) showed an enhanced reduction in TSLP expression, whereas the decrease in K17 protein expression was impaired in psoriatic keratinocytes. Although the here examined siRNA combination could still be further improved, our study proved already in vitro the clinical potential of targeting multiple genes at once, each playing a different role in a complex disease such as psoriasis.
Keywords
combination therapy, lipid-based delivery system, reconstructed human skin, small interfering RNA, topical treatment, EPIDERMAL-KERATINOCYTES, TNF-ALPHA, THERAPEUTICS, DIFFERENTIATION, EXPRESSION, THERAPY, FUTURE, GENES, IL-22, CELLS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 569.85 KB

Citation

Please use this url to cite or link to this publication:

MLA
Desmet, Eline et al. “Towards the Development of a RNAi-based Topical Treatment for Psoriasis : Proof-of-concept in a 3D Psoriasis Skin Model.” EXPERIMENTAL DERMATOLOGY 27.5 (2018): 463–469. Print.
APA
Desmet, Eline, Van Gele, M., Grine, L., Remaut, K., & Lambert, J. (2018). Towards the development of a RNAi-based topical treatment for psoriasis : proof-of-concept in a 3D psoriasis skin model. EXPERIMENTAL DERMATOLOGY, 27(5), 463–469.
Chicago author-date
Desmet, Eline, Mireille Van Gele, Lynda Grine, Katrien Remaut, and Jo Lambert. 2018. “Towards the Development of a RNAi-based Topical Treatment for Psoriasis : Proof-of-concept in a 3D Psoriasis Skin Model.” Experimental Dermatology 27 (5): 463–469.
Chicago author-date (all authors)
Desmet, Eline, Mireille Van Gele, Lynda Grine, Katrien Remaut, and Jo Lambert. 2018. “Towards the Development of a RNAi-based Topical Treatment for Psoriasis : Proof-of-concept in a 3D Psoriasis Skin Model.” Experimental Dermatology 27 (5): 463–469.
Vancouver
1.
Desmet E, Van Gele M, Grine L, Remaut K, Lambert J. Towards the development of a RNAi-based topical treatment for psoriasis : proof-of-concept in a 3D psoriasis skin model. EXPERIMENTAL DERMATOLOGY. 2018;27(5):463–9.
IEEE
[1]
E. Desmet, M. Van Gele, L. Grine, K. Remaut, and J. Lambert, “Towards the development of a RNAi-based topical treatment for psoriasis : proof-of-concept in a 3D psoriasis skin model,” EXPERIMENTAL DERMATOLOGY, vol. 27, no. 5, pp. 463–469, 2018.
@article{8566657,
  abstract     = {RNA interference has emerged as a powerful tool for therapeutic gene silencing, as it offers the possibility to silence virtually any known pathology-causing gene. However, in vivo delivery of RNAi molecules is hampered by their unfavourable physicochemical characteristics and susceptibility to degradation by endogenous enzymes. To overcome these limitations, we recently developed an elastic liposomal formulation, called DDC642, as topical delivery system of therapeutic RNAi molecules for skin disorders. In this study, we validated the therapeutic efficacy of DDC642-encapsulated RNAi molecules in the treatment of psoriasis using 3 different in vitro models: a standardized keratinocyte monolayer culture, psoriasis-induced keratinocytes and a psoriasis-reconstructed skin model. Four genes (IL22RA1, KRT17, DEFB4 and TSLP), known to be upregulated in psoriatic lesions, and thereby key players in psoriasis pathogenesis were selected. Moreover, the possibility of using a combined siRNA therapy in the topical treatment of psoriasis was explored. Results indicate a successful gene silencing of each different target, both at mRNA and protein levels. Additionally, siRNA-DDC642 treatment resulted in a reduced expression of specific psoriasis markers, indicating their potential in future therapeutic approach. The examined siRNA combination (ie simultaneous knockdown of KRT17, DEFB4 and TSLP) showed an enhanced reduction in TSLP expression, whereas the decrease in K17 protein expression was impaired in psoriatic keratinocytes. Although the here examined siRNA combination could still be further improved, our study proved already in vitro the clinical potential of targeting multiple genes at once, each playing a different role in a complex disease such as psoriasis.},
  author       = {Desmet, Eline and Van Gele, Mireille and Grine, Lynda and Remaut, Katrien and Lambert, Jo},
  issn         = {0906-6705},
  journal      = {EXPERIMENTAL DERMATOLOGY},
  keywords     = {combination therapy,lipid-based delivery system,reconstructed human skin,small interfering RNA,topical treatment,EPIDERMAL-KERATINOCYTES,TNF-ALPHA,THERAPEUTICS,DIFFERENTIATION,EXPRESSION,THERAPY,FUTURE,GENES,IL-22,CELLS},
  language     = {eng},
  number       = {5},
  pages        = {463--469},
  title        = {Towards the development of a RNAi-based topical treatment for psoriasis : proof-of-concept in a 3D psoriasis skin model},
  url          = {http://dx.doi.org/10.1111/exd.13414},
  volume       = {27},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: